-+ 0.00%
-+ 0.00%
-+ 0.00%

DUPIXENT® (DUPILUMAB) APPROVED IN JAPAN AS THE FIRST TARGETED MEDICINE TO TREAT ADULTS WITH BULLOUS PEMPHIGOID (BP)

Reuters·03/24/2026 06:00:01

Please log in to view news